Choosing ImmunotherapyVideo Categories: 2018 AONN Midyear, Immunotherapy, and Video Library
Dr Morganna Freeman outlines some of the criteria used in deciding which patients will most benefit from immunotherapy.
The publishers of Personalized Medicine in Oncology (PMO) invite you to watch an interview with Dr Lawrence Weiss, Medical Director at Clarient Diagnostic Services, discussing personalized medicine in diagnostics and with MultiOmyx™.
Dr Sanjiv Agarwala discusses the usefulness of MSI and TMB as novel biomarkers for various cancer types. His argument is that the first FDA approval of a therapy based on MSI rather than tumor type makes this biomarker useful, but TMB is not yet ready for “prime time.”